Phase 1 Trial of JTM201 in Subjects With Post-stroke Upper Limb Spasticity

Exclusion Criteria

• •Any medical condition that may affect neuromuscular function (eg, myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis)
• •Subjects with dysphagia that, in the judgment of the investigator, may interfere with study participation
• •Subjects with fixed joint/muscle contracture\* at the planned injection sites
• •Subjects with severe muscle atrophy at the planned injection sites
• •Subjects with skin abnormalities such as infection, skin disease, or scar at the planned injection sites
• •History of acute deterioration in pulmonary function within 3 months prior to screening \[including but not limited to hospitalization due to asthma or COPD exacerbation, or pneumonia\]
• •History of chemodenervation using phenol or alcohol, or surgery at the planned injection site within 24 weeks prior to screening, or scheduled for treatment or surgical intervention during the study
• •History of tendon lengthening of the study limb within 24 weeks prior to screening, or scheduled surgical intervention at the planned injection site during the study
• •Previous treatment with botulinum toxin of any serotype in any area within 24 weeks prior to screening
• •Subjects with ongoing treatment with intrathecal Baclofen
• •Subjects who require the administration of concomitant medications or implementation of concomitant therapies during the study period